Oramed Pharmaceuticals Inc

(NASDAQ:ORMP)

Latest On Oramed Pharmaceuticals Inc (ORMP):

Date/Time Type Description Signal Details
2023-05-17 06:43 ESTNewsOramed: Buyer BewareN/A
2023-05-15 13:32 ESTNewsOramed's Chinese partner HTIT completes phase 3 oral insulin trial; submits marketing Application in China; stock Up 17%N/A
2023-05-03 14:04 ESTNewsInvesting millions, Ben Shapiro joins board of Oramed PharmaceuticalsN/A
2023-01-17 23:01 ESTNewsOramed stock falls 10% as Wainwright cuts rating on potential halt of drug trialN/A
2023-01-15 11:48 ESTNewsEvaluating Oramed After Their P3 Type 2 Diabetes Trial FailureN/A
2023-01-12 13:04 ESTNewsOramed stock slumps ~70% as diabetes drug fails phase 3 studyN/A
2023-01-04 22:42 ESTNewsOramed granted patent for combination therapy GLP-1 & insulin to treat diabetesN/A
2022-12-07 18:44 ESTNewsOramed: NASH Biotech Play With Added BonusN/A
2022-11-27 23:19 ESTNewsAre needle-free COVID vaccines our way out of the pandemic?N/A
2022-11-18 18:48 ESTNewsOramed inks contract with Medicox to distribute oral insulin in South KoreaN/A
2022-11-10 21:30 ESTNewsOramed Pharmaceuticals GAAP EPS of -$0.18, revenue of $2.02MN/A
2022-10-07 19:45 ESTNewsOramed oral COVID vaccine shows promise in phase 1 trialN/A
2022-09-21 12:40 ESTNewsOramed: Oral Insulin For Type 2 Diabetes May Become A RealityN/A
2022-09-13 15:52 ESTNewsOramed's phase 2 trial of oral insulin candidate to reduce liver fat meets main goalN/A
2022-09-10 02:10 ESTNewsOramed to hand Korean rights for insulin capsuleN/A
2022-07-09 00:04 ESTNewsOramed, MyMD surge on plans for early-stage oral COVID vaccine data release in Q3N/A
2022-07-07 17:06 ESTNewsOramed to report early-stage trial data for oral COVID-19 shot in 3QN/A
2022-05-25 01:10 ESTNewsOramed granted U.S. combination therapy patent for oral insulinN/A
2022-04-15 02:27 ESTNewsOramed And Oral Insulin: Can This Small Company Really Do It?N/A
2022-02-27 21:46 ESTNewsOramed Pharmaceuticals (ORMP) Investor Presentation - SlideshowN/A
2021-12-29 07:15 ESTNewsOramed's subsidiary inks purchase deal for 10M doses of oral COVID-19 vaccines in Southeast AsiaN/A
2021-12-22 22:07 ESTNewsOramed And The Hurdles Of Developing Oral InsulinN/A
2021-11-18 20:44 ESTNewsOramed, Genomma Lab joint venture to commercialize oral COVID vaccine in MexicoN/A
2021-11-03 16:58 ESTNewsOramed falls after announcing $50 million at-the-market offeringN/A
2021-10-29 22:34 ESTNewsOravax Medical gets clearance for Phase 1 oral COVID-19 vaccine trial in South AfricaN/A
2021-10-20 13:28 ESTNewsOramed's Phase 2 oral insulin NASH trial reaches over 50% enrollmentN/A
2021-10-05 12:28 ESTNewsOramed: Prospects Still Remain Despite Merck-Ridgeback's ProgressN/A
2021-09-03 20:35 ESTNewsVaxart and Oramed: Two oral COVID-19 vaccine playsN/A
2021-09-03 00:25 ESTNewsPfizer, Merck test oral COVID-19 therapeutics; Oral vaccine on the way?N/A
2021-08-25 02:36 ESTNewsOramed provides enrollment update for late-stage ORMD-0801 diabetes studyN/A
2021-08-16 22:49 ESTNewsOramed announces publication of Phase 2 data for oral insulin candidateN/A
2021-08-11 06:06 ESTNewsOravax Medical is preparing to commence clinical trials for oral COVID-19 vaccineN/A
2021-08-10 09:27 ESTNewsJim Cramer comments propel Oramed PharmaceuticalsN/A
2021-07-29 23:33 ESTNewsOramed Pharmaceuticals names chief commercial officerN/A
2021-07-21 19:09 ESTNewsOramed Pharmaceuticals: Interesting Late-Stage Oral Insulin DeveloperN/A
2021-07-21 19:05 ESTNewsOramed reaches 50% enrollment in late-stage oral insulin studyN/A
2021-07-21 18:52 ESTNewsOramed Pharmaceuticals to join Russell 2000 and 3000 IndexN/A
2021-07-21 18:28 ESTNewsOramed subsidiary to start clinical trials for its oral COVID-19 vaccine candidateN/A
2021-04-21 04:19 ESTNewsOramed Pharma initiated buy at Canaccord citing the potential of oral insulin therapyN/A
2021-03-24 04:16 ESTNewsOramed initiates second phase 3 study of oral insulin candidate; shares up 14%N/A
2021-03-20 00:15 ESTNewsOramed to form Oravax Medical JV to develop oral COVID-19 vaccinesN/A
2021-03-17 05:40 ESTNewsOramed reaches 25% enrollment in late-stage ORMD-0801 studyN/A
2021-02-16 12:08 ESTAnalyst RatingThe Analyst Target Price has increased from $15.6 to $16.83.Buy
2021-01-28 12:18 ESTAnalyst RatingThe Analyst Target Price has increased from $14.4 to $15.6.Buy
2021-01-27 19:27 ESTNewsData from Oramed's oral insulin in late-stage diabetes study expected in 2022N/A
2021-01-27 12:23 ESTAnalyst RatingThe Analyst Target Price has increased from $12.6 to $14.4.Buy
2021-01-16 00:23 ESTFinancialsCompany financials have been released.Neutral
2021-01-15 08:18 ESTEarnings EstimateAn EPS average of -$0.18 is estimated for the quarter ending on May 31, 2021.Buy
2021-01-14 23:42 ESTNewsOramed Pharmaceuticals EPS beats by $0.42, revenue in-lineN/A
2020-12-23 17:27 ESTNewsOramed's obesity drug candidate shows decrease in glucose levelsN/A

About Oramed Pharmaceuticals Inc (ORMP):

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

ORMP Quotes by TradingView

See Advanced Chart

General

  • Name Oramed Pharmaceuticals Inc
  • Symbol ORMP
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Last Split Factor1:12
  • Last Split Date2013-01-23
  • Fiscal Year EndAugust
  • IPO Date2006-04-21
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.oramed.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 80.17
  • Price/Book (Most Recent Quarter) 10.23
  • Enterprise Value Revenue 98.01
View More

Financials

  • Most Recent Quarter 2020-11-30
  • Current Year EPS Estimate -$0.50
  • Next Year EPS Estimate -$0.73
  • Operating Margin -559%
  • Return on Assets -26%
  • Return on Equity -64%
  • Revenue 2.71 million
  • Earnings Per Share -$0.87
  • Revenue Per Share $0.12
  • Gross Profit 2.71 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 273.73 million
  • EBITDA -15430000
  • Analyst Target Price $16.83
  • Book Value Per Share $1.19
View More

Share Statistics

  • Shares Outstanding 29.37 million
  • Shares Float 24.41 million
  • % Held by Insiders 1391%
  • % Held by Institutions 14.5%
  • Shares Short 1.74 million
  • Shares Short Prior Month 1.82 million
  • Short Ratio 1.87
  • Short % of Float 7%
  • Short % of Shares Outstanding 6%
View More

Technicals

  • Beta 1.79
  • 52 Week High $11.71
  • 52 Week Low $2.4
  • 50 Day Moving Average 9.25
  • 200 Day Moving Average 4.92
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Oramed Pharmaceuticals Inc (ORMP) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Oramed Pharmaceuticals Inc (ORMP) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-11-302021-01-14$N/A-$0.23-$0.19-18.99%
2020-08-312020-11-24$681000-$0.10-$0.1323.08%
2020-05-312020-07-07$N/A-$0.10-$0.2050%
2020-02-292020-04-06$674000-$0.21-$0.18-20%
2019-11-302020-01-09$674000-$0.15-$0.2538.78%
2019-08-312019-11-27$681000-$0.13-$0.2546.94%
2019-05-312019-07-10$682000-$0.23-$0.244.17%
2019-02-282019-04-10$666000-$0.21-$0.2720.75%
2018-11-302019-01-14$674000-$0.25-$0.20-28.21%
2018-08-312018-11-28$617000-$0.18-$0.3039.33%
2018-05-312018-07-12$617000-$0.30-$0.27-12.49%
2018-02-282018-04-09$604000-$0.20-$0.3032.2%
2017-11-302018-01-11$611000-$0.18-$0.2114.29%
2017-08-312017-11-29$3.07 million-$0.20-$0.2623.08%
2017-05-312017-07-06$-617000-$0.15-$0.2744.44%
2017-02-282017-04-05$611000-$0.24-$0.19-26.32%
2016-11-302017-01-11$-610000-$0.20-$0.12-66.67%
2016-08-312016-11-25$353000-$0.37-$0.17-124.24%
2016-05-312016-07-06$163000-$0.15-$0.1920%
2016-02-292016-04-06$125000-$0.14-$0.1926.32%
2015-11-302016-01-13$N/A-$0.21-$0.19-10.53%
2015-08-312015-11-25$N/A-$0.19-$0.18-5.56%
2015-05-312015-07-01$N/A-$0.15-$0.1816.67%
2015-02-282015-04-03$N/A-$0.15-$0.2231.82%
2014-11-302015-01-08$N/A-$0.19-$0.219.52%
2014-08-312014-11-14$N/A-$0.17-$0.2015%
2014-05-312014-07-14$N/A-$0.18-$0.15-20%
2014-02-282014-04-10$N/A-$0.12-$0.1833.33%
2013-11-302014-01-14$N/A-$0.14-$0.1612.5%
2013-08-312013-10-30$N/A-$0.11
2013-05-312013-07-31$N/A-$0.17
2013-02-282013-02-28$N/A-$0.17
2012-11-302012-11-30$N/A-$0.14
2012-08-312012-08-31$-141143-$0.23
2012-05-312012-05-31$N/A-$0.09
2012-02-292012-02-29$-43111-$0.17
2011-11-302011-11-30$N/A-$0.08
2011-08-312011-08-31$N/A-$0.14
2011-05-312011-05-31$N/A$0.08
2011-02-282011-02-28$N/A-$0.12
2010-11-302010-11-30$N/A-$0.12
2010-08-312010-08-31-$0.25
2010-05-312010-05-31-$0.17
2010-02-282010-02-28-$0.08
2009-11-302009-11-30-$0.13
2009-08-312009-08-31-$0.08
2009-05-312009-05-31-$0.11
2009-02-282009-02-28-$0.14
2008-11-302008-11-30-$0.25
2008-08-312008-08-31$-0.00
2008-05-312008-05-31-$0.21
2008-02-292008-02-29-$0.09
2007-11-302007-11-30-$0.09
2007-08-312007-08-31-$0.72
2007-05-312007-05-31-$0.09
2007-02-282007-02-28-$0.10
2006-11-302006-11-30-$0.02
2006-08-312006-08-31-$0.08
2006-05-312006-05-31-$0.05
2006-02-282006-02-28$-0.00
2005-11-302005-11-30$-0.00

Oramed Pharmaceuticals Inc (ORMP) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Oramed Pharmaceuticals Inc (ORMP) Chart:

ORMP chart by TradingView

Oramed Pharmaceuticals Inc (ORMP) News:

Below you will find a list of latest news for Oramed Pharmaceuticals Inc (ORMP) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Oramed Pharmaceuticals Inc (ORMP) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50.05CALL100 8528.14FALSE-0.05-0.5
2024-05-1750.05CALL0 18030FALSE00
2024-05-177.50.08CALL0 210FALSE00
2024-05-172.50.45PUT0 1357.3TRUE00
2024-05-1752.72PUT0 32475.79TRUE00
2024-05-177.50PUT0 0682.79TRUE00
2024-06-212.50CALL0 00FALSE00
2024-06-2150.05CALL50 1122.16FALSE0.050
2024-06-217.50CALL0 00FALSE00
2024-06-212.50PUT0 075.69TRUE00
2024-06-2150PUT0 0377.68TRUE00
2024-06-217.50PUT0 0445.27TRUE00
2024-08-162.50.3CALL1 10655.58FALSE0.30
2024-08-1650.11CALL206 1871104.81FALSE0.110
2024-08-167.50.51CALL0 1060FALSE00
2024-08-162.50.35PUT1 464.4TRUE0.350
2024-08-1652.53PUT6 30652.12TRUE2.530
2024-08-167.50PUT0 0591.25TRUE00
2024-11-152.54.1CALL0 192.56FALSE00
2024-11-1550.33CALL0 188.99FALSE00
2024-11-157.50CALL0 00FALSE00
2024-11-152.50.4PUT0 192.61TRUE00
2024-11-1550PUT0 0146.91TRUE00
2024-11-157.50PUT0 0260.25TRUE00

Latest ORMP Trades:

Date Shares Price
Jun 13, 2022 7:58 PM EST90$4.005
Jun 13, 2022 7:59 PM EST400$4
Jun 13, 2022 7:59 PM EST100$3.995
Jun 13, 2022 7:59 PM EST200$3.995
Jun 13, 2022 7:59 PM EST99$3.995

Oramed Pharmaceuticals Inc (ORMP) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020016305/0001213900-20-016305-index.htm
2017-07-28UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1176309/000000000017026732/0000000000-17-026732-index.htm
2020-02-04UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1176309/000000000020001091/0000000000-20-001091-index.htm
2018-07-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1176309/000091957418004721/0000919574-18-004721-index.htm
2017-07-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017007168/0001213900-17-007168-index.htm
2017-07-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1176309/000121390017007202/0001213900-17-007202-index.htm
2017-07-20PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017007770/0001213900-17-007770-index.htm
2017-07-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390017007808/0001213900-17-007808-index.htm
2017-07-28PRER14APreliminary Proxy Soliciting materialshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017008003/0001213900-17-008003-index.htm
2017-08-01DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017008089/0001213900-17-008089-index.htm
2017-08-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017008213/0001213900-17-008213-index.htm
2017-08-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017008214/0001213900-17-008214-index.htm
2017-08-033Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017008215/0001213900-17-008215-index.htm
2017-08-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017008889/0001213900-17-008889-index.htm
2017-08-214Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017008982/0001213900-17-008982-index.htm
2017-08-28424B7Prospectus [Rule 424(b)(7)]https://www.sec.gov/Archives/edgar/data/1176309/000121390017009231/0001213900-17-009231-index.htm
2017-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390017009427/0001213900-17-009427-index.htm
2017-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390017009429/0001213900-17-009429-index.htm
2017-10-16424B7Prospectus [Rule 424(b)(7)]https://www.sec.gov/Archives/edgar/data/1176309/000121390017010619/0001213900-17-010619-index.htm
2017-10-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017010951/0001213900-17-010951-index.htm
2017-11-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390017011195/0001213900-17-011195-index.htm
2017-11-03424B7Prospectus [Rule 424(b)(7)]https://www.sec.gov/Archives/edgar/data/1176309/000121390017011295/0001213900-17-011295-index.htm
2017-11-2910-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1176309/000121390017012754/0001213900-17-012754-index.htm
2018-01-1110-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1176309/000121390018000390/0001213900-18-000390-index.htm
2018-02-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390018001245/0001213900-18-001245-index.htm
2018-02-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390018001247/0001213900-18-001247-index.htm
2018-02-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390018001250/0001213900-18-001250-index.htm
2018-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390018002084/0001213900-18-002084-index.htm
2018-04-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1176309/000121390018004196/0001213900-18-004196-index.htm
2018-04-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390018004250/0001213900-18-004250-index.htm
2018-05-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390018005618/0001213900-18-005618-index.htm
2018-07-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390018008780/0001213900-18-008780-index.htm
2018-07-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1176309/000121390018008784/0001213900-18-008784-index.htm
2018-07-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390018009128/0001213900-18-009128-index.htm
2018-07-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1176309/000121390018009132/0001213900-18-009132-index.htm
2018-07-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1176309/000121390018009486/0001213900-18-009486-index.htm
2018-07-20SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1176309/000121390018009488/0001213900-18-009488-index.htm
2018-07-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1176309/000121390018009875/0001213900-18-009875-index.htm
2018-08-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390018010829/0001213900-18-010829-index.htm
2018-08-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390018011939/0001213900-18-011939-index.htm
2018-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390018012630/0001213900-18-012630-index.htm
2018-11-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390018015178/0001213900-18-015178-index.htm
2018-11-203Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390018016314/0001213900-18-016314-index.htm
2018-11-2810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1176309/000121390018016666/0001213900-18-016666-index.htm
2018-12-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390018017333/0001213900-18-017333-index.htm
2019-01-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1176309/000121390019000691/0001213900-19-000691-index.htm
2019-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019003333/0001213900-19-003333-index.htm
2019-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019003334/0001213900-19-003334-index.htm
2019-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019003337/0001213900-19-003337-index.htm
2019-02-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019003338/0001213900-19-003338-index.htm
2019-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390019004051/0001213900-19-004051-index.htm
2019-03-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390019005120/0001213900-19-005120-index.htm
2019-04-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1176309/000121390019006121/0001213900-19-006121-index.htm
2019-04-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019006288/0001213900-19-006288-index.htm
2019-04-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390019006512/0001213900-19-006512-index.htm
2019-04-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019006513/0001213900-19-006513-index.htm
2019-05-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390019009033/0001213900-19-009033-index.htm
2019-06-053Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019010104/0001213900-19-010104-index.htm
2019-06-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019011646/0001213900-19-011646-index.htm
2019-07-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390019011856/0001213900-19-011856-index.htm
2019-07-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1176309/000121390019012456/0001213900-19-012456-index.htm
2019-07-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019012780/0001213900-19-012780-index.htm
2019-07-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019013085/0001213900-19-013085-index.htm
2019-07-193Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019013179/0001213900-19-013179-index.htm
2019-07-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390019013773/0001213900-19-013773-index.htm
2019-08-06DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019014679/0001213900-19-014679-index.htm
2019-08-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390019016472/0001213900-19-016472-index.htm
2019-09-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390019017287/0001213900-19-017287-index.htm
2019-09-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1176309/000121390019017289/0001213900-19-017289-index.htm
2019-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019017770/0001213900-19-017770-index.htm
2019-09-163Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019018195/0001213900-19-018195-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019018196/0001213900-19-018196-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019018197/0001213900-19-018197-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019018198/0001213900-19-018198-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019018199/0001213900-19-018199-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019018200/0001213900-19-018200-index.htm
2019-10-23S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019020923/0001213900-19-020923-index.htm
2019-11-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390019022717/0001213900-19-022717-index.htm
2019-11-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1176309/000121390019024940/0001213900-19-024940-index.htm
2019-12-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390019025444/0001213900-19-025444-index.htm
2019-12-113Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390019025901/0001213900-19-025901-index.htm
2020-01-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1176309/000121390020000631/0001213900-20-000631-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020000983/0001213900-20-000983-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020000984/0001213900-20-000984-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020000985/0001213900-20-000985-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020000988/0001213900-20-000988-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020000989/0001213900-20-000989-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020000991/0001213900-20-000991-index.htm
2020-01-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020000993/0001213900-20-000993-index.htm
2020-01-31S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1176309/000121390020002261/0001213900-20-002261-index.htm
2020-02-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1176309/000121390020002759/0001213900-20-002759-index.htm
2020-02-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1176309/000121390020003130/0001213900-20-003130-index.htm
2020-02-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020003270/0001213900-20-003270-index.htm
2020-02-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390020004778/0001213900-20-004778-index.htm
2020-02-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1176309/000121390020004816/0001213900-20-004816-index.htm
2020-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390020005018/0001213900-20-005018-index.htm
2020-03-02424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1176309/000121390020005116/0001213900-20-005116-index.htm
2020-04-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1176309/000121390020008653/0001213900-20-008653-index.htm
2020-04-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390020008913/0001213900-20-008913-index.htm
2020-06-16PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020015109/0001213900-20-015109-index.htm
2020-06-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020016305/0001213900-20-016305-index.htm
2020-07-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1176309/000121390020016864/0001213900-20-016864-index.htm
2020-07-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390020017505/0001213900-20-017505-index.htm
2020-08-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390020020031/0001213900-20-020031-index.htm
2020-08-11S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1176309/000121390020021429/0001213900-20-021429-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390020024016/0001213900-20-024016-index.htm
2020-09-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390020025857/0001213900-20-025857-index.htm
2020-09-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390020027361/0001213900-20-027361-index.htm
2020-10-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1176309/000121390020032805/0001213900-20-032805-index.htm
2018-07-13SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1176309/000138713118003118/0001387131-18-003118-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1176309/000138713119001135/0001387131-19-001135-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1176309/000138713120001660/0001387131-20-001660-index.htm
2018-07-03SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1176309/000153561018000095/0001535610-18-000095-index.htm
2019-01-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1176309/000153561019000041/0001535610-19-000041-index.htm
2020-01-21SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1176309/000153561020000050/0001535610-20-000050-index.htm
2020-02-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1176309/999999999520000309/9999999995-20-000309-index.htm
2018-04-16CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1176309/999999999718004782/9999999997-18-004782-index.htm
2020-05-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1176309/999999999720002359/9999999997-20-002359-index.htm
2020-05-01CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1176309/999999999720002360/9999999997-20-002360-index.htm

Oramed Pharmaceuticals Inc (ORMP) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Oramed Pharmaceuticals Inc (ORMP). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1391%
Institutional Ownership: 1450%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-08-09Aviad FriedmanDirectorBuy500.004.822,410.0010,191.00https://www.sec.gov/Archives/edgar/data/1176309/000121390018010829/0001213900-18-010829-index.htm
2018-08-09Aviad FriedmanDirectorBuy2,000.004.989,960.0012,191.00https://www.sec.gov/Archives/edgar/data/1176309/000121390018010829/0001213900-18-010829-index.htm
2017-08-17David Mark SlagerDirectorBuy112,613.003.77424,055.511,299,436.00https://www.sec.gov/Archives/edgar/data/1176309/000121390017008982/0001213900-17-008982-index.htm
2017-10-31David Mark SlagerDirectorBuy16,892.003.7763,608.521,316,328.00https://www.sec.gov/Archives/edgar/data/1176309/000121390017011195/0001213900-17-011195-index.htm
2017-08-02Xiaopeng LiDirectorBuy89,636.008.50761,906.00206,350.00https://www.sec.gov/Archives/edgar/data/1176309/000121390017008214/0001213900-17-008214-index.htm
2017-08-15Leonard SankDirectorBuy11,262.006.0067,572.00282,158.00https://www.sec.gov/Archives/edgar/data/1176309/000121390017008889/0001213900-17-008889-index.htm
2017-10-23Leonard SankDirectorBuy5,631.006.0033,786.00287,789.00https://www.sec.gov/Archives/edgar/data/1176309/000121390017010951/0001213900-17-010951-index.htm
2017-10-23Leonard SankDirectorBuy6,373.006.0038,238.00294,162.00https://www.sec.gov/Archives/edgar/data/1176309/000121390017010951/0001213900-17-010951-index.htm
2019-07-11Leonard SankDirectorBuy1,320.003.224,250.40295,482.00https://www.sec.gov/Archives/edgar/data/1176309/000121390019012780/0001213900-19-012780-index.htm
2019-07-16Leonard SankDirectorBuy20,000.003.4769,316.00315,482.00https://www.sec.gov/Archives/edgar/data/1176309/000121390019013085/0001213900-19-013085-index.htm
2019-07-17Leonard SankDirectorBuy20,000.003.5871,562.00335,482.00https://www.sec.gov/Archives/edgar/data/1176309/000121390019013085/0001213900-19-013085-index.htm
2019-07-17Leonard SankDirectorBuy10,020.003.7437,496.84345,502.00https://www.sec.gov/Archives/edgar/data/1176309/000121390019013085/0001213900-19-013085-index.htm
2019-07-18Leonard SankDirectorBuy4,497.003.8617,335.94349,999.00https://www.sec.gov/Archives/edgar/data/1176309/000121390019013085/0001213900-19-013085-index.htm
2019-09-09Leonard SankDirectorBuy15,000.002.9043,500.00364,999.00https://www.sec.gov/Archives/edgar/data/1176309/000121390019017770/0001213900-19-017770-index.htm
2019-09-09Leonard SankDirectorBuy10,000.002.9529,500.00374,999.00https://www.sec.gov/Archives/edgar/data/1176309/000121390019017770/0001213900-19-017770-index.htm
2017-08-02Miriam KidronChief Scientific OfficerSell89,636.008.50761,906.0075,000.00https://www.sec.gov/Archives/edgar/data/1176309/000121390017008213/0001213900-17-008213-index.htm
2018-07-10NADAV KIDRONPresident and CEOSell61.005.98364.97958,087.00https://www.sec.gov/Archives/edgar/data/1176309/000121390018009128/0001213900-18-009128-index.htm
2018-07-11NADAV KIDRONPresident and CEOBuy122.005.92722.18958,209.00https://www.sec.gov/Archives/edgar/data/1176309/000121390018009128/0001213900-18-009128-index.htm